Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

Access Course


892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.


This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.

The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).



Approximate Time to Complete: 30 minutes


Credit Available: Mar. 09, 2018 - Mar. 09, 2019


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Increase knowledge regarding the role of immune checkpoint inhibitors in the management of advanced HCC
  • Increase knowledge regarding identification of immune-related adverse events in patients with HCC who receive a checkpoint inhibitor
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50